All Antiretrovirals in US Ought to Be Tested for HIV Resistance, FDA Suggests in New Guidance | GenomeWeb

All antiretroviral drugs in development and already on the market in the United States should be tested for HIV resistance, the US Food and Drug Administration suggested in a new draft guidance for industry.

The document, filed on Nov. 26, is designed to encourage drug makers to collect data that, when made publicly available in product labeling and FDA reviews, could be useful to diagnostics firms, physicians, regulatory agencies, and the drug makers themselves.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.